Dr Christopher L Fillmore, MD | |
105 Grant Cir, Suite 133, Offutt A F B, NE 68113-4041 | |
(402) 294-7346 | |
Not Available |
Full Name | Dr Christopher L Fillmore |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Aerospace Medicine |
Location | 105 Grant Cir, Offutt A F B, Nebraska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629296371 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083A0100X | Preventive Medicine - Aerospace Medicine | 24332 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Christopher L Fillmore, MD 105 Grant Cir, Suite 133, Offutt A F B, NE 68113-4041 Ph: (402) 294-7346 | Dr Christopher L Fillmore, MD 105 Grant Cir, Suite 133, Offutt A F B, NE 68113-4041 Ph: (402) 294-7346 |
News Archive
COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.
CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ Insulin Delivery Device.
Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.
Novavax, Inc. has announced that is has signed a non-exclusive, worldwide license agreement with Wyeth, to obtain rights to a patent application covering virus-like particle (VLP) technology for use in human vaccines in certain fields of use.
› Verified 1 days ago